Charles River Laboratories International, Inc. cash flow to debt ratio of 24.06% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Charles River Laboratories International, Inc.'s free cash flow has increased 3.37% from $501.61M last year to $518.49M, signaling increasing performance

Charles River Laboratories International, Inc.'s debt to equity ratio is 1.07, which means that the company's assets are unhealthy financed, signaling financial risk.

Charles River Laboratories International, Inc.'s debt has increased relative to shareholder equity from 0.79 last year to 1.07 today, signaling weakened financials

Charles River Laboratories International, Inc. has a net debt to EBITDA ratio of 6.94x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Charles River Laboratories International, Inc.'s interest coverage ratio of 4.65 indicates that earnings with good margin can cover interest payments on company debt

Charles River Laboratories International, Inc.'s profit margin has decreased (2.45K%) in the last year from 0.25% to -5.96%, signaling decreasing performance

Charles River Laboratories International, Inc.'s short-term assets of $1.45B exceed its short-term liabilities of $1.12B

Charles River Laboratories International, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Charles River Laboratories International, Inc.'s return on equity of -7.72%, is lower than 15.00%, indicating bad performance

Charles River Laboratories International, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Charles River Laboratories International, Inc. had positive net income in 4 out of 5 years, indicating stable and consistent earnings

Charles River Laboratories International, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Charles River Laboratories International, Inc. has a free cash flow yield of 3.89%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Charles River Laboratories International, Inc.'s yearly earnings has decreased 1.50K% since last year from $10.30M to $-144.34M, signaling decreasing performance

Charles River Laboratories International, Inc.'s yearly revenue has decreased 0.85% since last year from $4.05B to $4.02B, signaling decreasing performance

ROIC 7.72% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Charles River Laboratories International, Inc.'s 3-year revenue CAGR of 0.33% is positive, indicating growing revenue over the past 3 years

Charles River Laboratories International, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Charles River Laboratories International, Inc. had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 103.57 based on Discounted Cash Flow model

Charles River Laboratories International, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 71.64 based on EBITDA multiple model

Charles River Laboratories International, Inc. has an EV/EBITDA ratio of 39.42x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 218.80 based on Earnings Fair Value model

Charles River Laboratories International, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Charles River Laboratories International, Inc. has a price-to-book ratio of 4.72x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Charles River Laboratories International, Inc. has a price-to-sales ratio of 3.36x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue